Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
1.090
+0.020 (1.87%)
At close: Mar 17, 2026, 4:00 PM EDT
1.100
+0.010 (0.92%)
After-hours: Mar 17, 2026, 4:10 PM EDT
Elutia Revenue
In the year 2025, Elutia had annual revenue of $12.29M, down -15.03%. Elutia had revenue of $3.27M in the quarter ending December 31, 2025, with 16.16% growth.
Revenue (ttm)
$18.89M
Revenue Growth
-2.96%
P/S Ratio
3.79
Revenue / Employee
$241,039
Employees
51
Market Cap
46.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.29M | -2.17M | -15.03% |
| Dec 31, 2024 | 14.47M | -10.28M | -41.54% |
| Dec 31, 2023 | 24.75M | 896.00K | 3.76% |
| Dec 31, 2022 | 23.85M | -23.54M | -49.68% |
| Dec 31, 2021 | 47.39M | 4.71M | 11.03% |
| Dec 31, 2020 | 42.68M | -219.00K | -0.51% |
| Dec 31, 2019 | 42.90M | 3.86M | 9.90% |
| Dec 31, 2018 | 39.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 436.97M |
| Outset Medical | 119.48M |
| Pulmonx | 90.50M |
| Cytosorbents | 36.98M |
| electroCore | 29.84M |
| Sensus Healthcare | 27.48M |
| Spectral AI | 23.17M |
| NeuroOne Medical Technologies | 11.72M |
ELUT News
- 19 hours ago - Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19 - GlobeNewsWire
- 4 days ago - Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process - GlobeNewsWire
- 13 days ago - Elutia Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 15 days ago - Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market - GlobeNewsWire
- 20 days ago - Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026 - GlobeNewsWire
- 27 days ago - Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™ - GlobeNewsWire